It's never bad news to have your results published in more articles, but I don't understand why PIQ need to keep demonstrating this. The business is marketing PromarkerD as "shelf ready" (and has been for years now, correct me if I am wrong), so why the need to keep validating I don't understand - can someone explain?
I would have thought at this point in time the announcements should be business deals related, not further validation? I'm just confused, the path to commercialisation is so cloudy for me....
Ann: PromarkerD clinical assay performance results published, page-3
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
-0.020(2.30%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 88.0¢ | 84.5¢ | $104.5K | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12500 | 85.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 2526 | 1 |
View Market Depth
| Last trade - 15.32pm 15/08/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |